Advancing Renal Amyloidosis Care: The Role of Modern Diagnostic Techniques with the Potential of Enhancing Patient Outcomes.
Charlotte DelrueAmélie DendoovenAnnelore VandendriesscheSpeeckaert ReinhartSander De BruyneMarijn M SpeeckaertPublished in: International journal of molecular sciences (2024)
Renal amyloidosis is a set of complex disorders characterized by the deposition of amyloid proteins in the kidneys, which causes gradual organ damage and potential kidney failure. Recent developments in diagnostic methods, particularly mass spectrometry and proteome profiling, have greatly improved the accuracy of amyloid typing, which is critical for disease management. These technologies provide extensive insights into the specific proteins involved, allowing for more targeted treatment approaches and better patient results. Despite these advances, problems remain, owing to the heterogeneous composition of amyloid proteins and the varying efficacy of treatments based on amyloid type. Access to sophisticated diagnostics and therapy varies greatly, highlighting the global difference in renal amyloidosis management. Future research is needed to investigate next-generation sequencing and gene-editing technologies, like clustered regularly interspaced short palindromic repeats (CRISPR), which promise more profound insights into the genetic basis of amyloidosis.
Keyphrases
- multiple myeloma
- mass spectrometry
- genome wide
- healthcare
- mental health
- oxidative stress
- case report
- gene expression
- stem cells
- high resolution
- single cell
- current status
- intellectual disability
- autism spectrum disorder
- mesenchymal stem cells
- machine learning
- big data
- health insurance
- cancer therapy
- cell therapy
- pain management
- genetic diversity
- climate change
- simultaneous determination
- circulating tumor
- chemotherapy induced